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1. Introduction 
During the past decade, important advances in the study of vitamin D have been made as 
vitamin D insufficiency is emerging as a clinical problem at a global level. In addition to 
its important role in skeletal development and maintenance, evidence is mounting  
that vitamin D produce beneficial effect on extraskeletal tissues. Recent evidence shows 
that vitamin D deficiencies contribute autoimmune diseases susceptibility and severity. 
This chapter will provide a systematic review of the importance of vitamin D in 
preexisting autoimmune diseases and whether its deficiency predispose patients to such 
disorders.  
2. Agenda 
 Overview of vitamin D: structure, sources and metabolism 
 Mechanism of vitamin D modulation of the immune responses, the difference between 
the bone and autoimmune tissues and the role of the vitamin D receptors.  
 The optimum serum level of vitamin D for skeletal health  
 Vitamin D and autoimmune disease: list of al the autoimmune diseases in which 
vitamin D is related to  
 Rheumatoogical 
 Non rheumatoogical 
 Vitamin D level and vitamin D supplementation in  
 RA 
 SLE 
 Scleroderma  
 Ankylosing spondylitis  
 Undifferentiated connective tissue disease  
 The immunological basis for the vitamin D role in preventing autoimmunity 
 Summary  
 Appendix: 1 Abbreviation  
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3. Vitamin D structure 
Vitamin D is a secosteroid which carries a structure similar to steroid except that two of 
the B-ring carbon atoms (C9 and 10) of the typical four steroid rings are broken, in this 
case by ultraviolet B sunlight. It is considered as a prohormone. The main source of 
vitamin D is denovosynthesis in the skin through ultravioletirradiation of 7-
dehydrocholesterol. It is biologically inert and mustbe metabolized to 25-hydroxyvitamin 
D3in the liver and then to1α, 25-dihydroxyvitamin D3in the kidney before it becomes 
functional Figure 1. (1, 2) 
 
Fig. 1. Structure of vitamin D3, or cholecalciferol 
4. Source of vitamin D 
The main source of vitamin D is de novo synthesis in the skin. Although vitamin D is present 
in food, dietary intake alone is often insufficient, supplying only 20% of the body’s 
requirements (3). It is not found in plant materials (eg, vegetables, fruits, or grains) and is 
present in low levels in meats and other animal food sources, except in rare cases such as 
fish liver oils (2).  
5. Metabolism of vitamin D 
The terminology related to the biochemistry of vitamin D can be confusing. Vitamin D has 2 
forms and several metabolites. The 2 forms are vitamin D2 and vitamin D3, also called 
ergocalciferol and cholecalciferol, respectively (4).  
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Both forms of vitamin D undergo identical metabolism (Figure 2). Some evidence indicates 
that vitamin D2 may be metabolized more rapidly than vitamin D3, but with regular daily 
intake they can be considered bioequivalent. Both forms of vitamin D are converted to 25-
hydroxyvitamin [25(OH)D] in the liver, and the serum level of 25(OH) D is measured to 
determine the adequacy of vitamin D status. In the kidney, 25(OH)D is hydroxylated to 1, 
25-dihydroxyvitamin D [1, 25(OH)2 D], which is the only biologically active form of vitamin 
D. Acting principally on the duodenum, 1, 25(OH)2 D increases calcium absorption. It also 
acts on bone cells, both osteoblasts and osteoclasts, to mobilize calcium. The synthesis of 1, 
25(OH)2 D is tightly regulated and stimulated primarily by serum parathyroid hormone 
(PTH) (4).  
 
Fig. 2. Vitamin D metabolism. Ca = calcium; 1, 25(OH)2D = 1, 25-dihydroxyvitamin D; 
25(OH)D =25-hydroxyvitamin D; PTH = parathyroid hormone.  
6. Vitamin D and autoimmune disease 
Vitamin D and its prohormones have been the focus of a growing number of studies in past 
years, demonstrating their function not only in calcium metabolism and bone formation, but 
also their interaction with the immune system. This is not surprising, since vitamin D 
receptors (VDR) are expressed in different tissues, such as brain, heart, skin, bowel, gonads, 
prostate, breasts, and the immune cells(3).  
Epidemiological studies have linked vitamin D status with autoimmune disease 
susceptibility and severity (5). Potentially, vitamin D deficiency could be a clinical problem 
of global proportions.  
www.intechopen.com
 
Insights and Perspectives in Rheumatology 
 
66
7. The mechanisms of vitamin D immunomodulation 
Dendritic cells (DCs) are primary targets for the immunomodulatory activity of 1, 
25(OH)2D3, as indicated by inhibited DC differentiation and maturation, leading to down-
regulated expression of MHC-II, costimulatory molecules (CD40, CD80 and CD86) and 
decreased production of IL-12. Moreover, 1, 25(OH)2D3 enhances IL-10 production and 
promotes DC apoptosis. Together, these effects of 1, 25(OH)2D3 inhibit DC-dependent T-cell 
activation. In particular, the active synthesis of 1, 25(OH)2D3 seems to exert an 
autoregulatory function by inhibiting the differentiation of monocyte precursors into 
immature DCs and the subsequent ability of the immature DCs to undergo terminal 
differentiation in response to maturation stimuli (Fig. 3).  
 
Fig. 3. Mechanisms involved in vitamin D modulation of the immune responses. DCs are 
primary targets for the immunomodulatory activity of 1, 25(OH)2D3, as indicated by 
inhibited DC differentiation and maturation, together with inhibition of differentiation of 
monocyte precursors into immature DCs. 1, 25(OH)2D3 suppresses Th1 (and Th17)driven 
cytokine responses, induces Treg cells, induces IL-4 production (Th2) and enhances NKT-
cell function. Differentiation and maturation of B cells is also inhibited. Th are CD4+ helper 
cell subsets (Th1, Th2, Th3-Treg, Th17) originating from naıve T cell (Th0). Thin arrows (left) 
indicate cytokines that induce differentiation of Th0 cells and thicker arrows (right) indicate 
cytokines produced by activated Th cell subsets. All T cells that have been tested express the 
VDR. B cells and NKT cells are also reported. The yellow circles indicate the 
cytokines/activities inhibited by vitamin D. On the contrary, the green circles indicate the 
cytokines enhanced by vitamin D.  
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Target cell population Actions mediated by 1. 25(oH)3 D3 
APCs (monocytes, macrophages, 
dendritic cells) 
inhibits the expression of class II MHC 
molecules inhibits the expression of 
costimulating molecules (CD40, CD80, and 
CD86) and other maturation inducing 
proteins (CD1a, CD83) increases chemotaxis 
and phagocytosis of monocytes and 
cytotoxicity against tumor cells and bacteria 
inhibits the maturation of dendritic cells 
induces tolerogenic dendritic cells capable 
of inducing Treg cells inhibits the release of 
IL-12 p70 inhibitsproinflammatory cytokines 
(IL-1 and TNF) by monocytes and 
macrophages.  
 
T lymphocytes inhibits T cell proliferation, secretion of 
cytokines, and progression of the cellular 
cycle from G1a to G1b increases the 
production of IL-4, IL-5, IL-10  
inhibits IL-12, INF-γ, and IL-2 
inhibits activation of antigenspecific T 
lymphocytes inhibits the expression of FasL 
by activated T lymphocytes 
 
B cells Expresses vDR 
Suppresses IgE secretion 
NK cells inhibits INF-γ 
Table 1. Actions of vitamin D in the immune system 
Tolerogenic DCs induced by a brief treatment with1, 25(OH)2D3or its analogues can induce 
CD4+ CD25+ T regulatory (Treg) cells that are able to mediate transplantation tolerance and 
arrest the development of autoimmunity (i. e. autoimmune diabetes). Tolerogenic DCs, 
however, may not always be necessarily involved in the generation of T-reg cells by VDR 
agonists and a combination of 1, 25(OH)2D3 and dexamethasone has been shown to induce 
naïve CD4+ T cells (Th0) to differentiate in vitro into IL-10-producing Treg cells, even in the 
absence of antigen-presenting cells. VDR agonists not only favour induction of CD4+CD25+ 
Treg cells and enhance their suppressive activity, but can also promote their recruitment at 
inflammatory sites. Furthermore, 1, 25(OH)2D3 treatments induced natural killer (NK) T-
cell functions in vitro and in vivo. NKT cells are early innate regulatory cells that can alter the 
outcome of autoimmunity. Therefore, two types of cells are induced by 1, 25(OH)2D3; the 
Treg and the NKT cells; induction of these regulatory cells and direct inhibition of Th1 cells 
are the mechanisms by which 1, 25(OH)2D3 suppresses experimental autoimmunity. In 
addition, treatment with VDR agonists inhibits the T-cell production of IL-17, a pro-
inflammatory cytokine that is produced by pathogenic T cells (Th17) in various models of 
organ-specific autoimmunity in the brain, heart, synovium and intestines.  
www.intechopen.com
 
Insights and Perspectives in Rheumatology 
 
68
nmol/L ng/mL Health status 
<30 <12 Associated with vitamin D deficiency, leading to rickets in infants 
and children and osteomalacia in adults 
30–50 12–20 Generally considered inadequate for bone and overall health in 
healthy individuals 
≥50 ≥20 Generally considered adequate for bone and overall health in 
healthy individuals 
>125 >50 Emerging evidence links potential adverse effects to such high 
levels, particularly >150 nmol/L (>60 ng/mL) 
Table 2. Classification of Vitamin D Status by 25(OH)D Concentration 
Interestingly, IL-17 production is sustained by IL-23, an IL-12 family member consisting of 
p19 and p40 chains, the latter of which is strongly inhibited by VDR agonists. Recently, 1, 
25(OH)2D3 treatment induced a significant inhibition of normal lymphoid cell progenitors 
growth of both T and B lineage and inhibited significantly also the growth of malignant 
Bcell lineage lymphoid progenitors, without inducing cytotoxic effect. More recently, by 
testing the effects of 1, 25(OH)2D3 on B-cell responses, it was found that it inhibited the 
ongoing proliferation of activated B cells and induced their apoptosis, whereas initial cell 
division was unimpeded.  
The generation of plasma cells and post-switch memory B cells was significantly inhibited 
by 1, 25(OH)2D3 although the up-regulation of genetic programs involved in B-cell 
differentiation was only modestly affected. B cells expressed mRNAs for proteins involved 
in vitamin D activity, including 1α-hydroxylase, 24-hydroxylase and the VDR, each of which 
was regulated by 1, 25(OH)2D3 and/or activation. Interestingly, 1, 25(OH)2D3 up-regulated 
the expression of p27, but not of p18 and p21, which may be important in regulating the 
proliferation of activated B cells and their subsequent differentiation in plasma cells.  
The net effect of 1, 25(OH)2D3 is enhancement of the innate immune system (protective) and 
down regulation of the adaptive immune system(acquired). Therefore, 25(OH)D deficiency 
may theoretically lead to autoimmune diseases.  
8. The optimum serum level of vitamin D for skeletal health  
Determination of vitamin D status is not based on measurement of serum 1, 25(OH)D 
concentrations. It is assessed by measuring the prohormone 25(OH)D, which is an indicator 
of supply rather than function. The most stable and plentiful metabolite of vitamin D in 
human serum, 25(OH)D, has a half-life of about 3 weeks, making it the most suitable 
indicator of vitamin D status (4). Using PTH elevation as a biomarker reflecting physiologic 
low levels of vitamin D, recent reports indicate that vitamin D deficiency would be more 
accurately defined as a 25D concentration of less than 32 ng/ml (80 nmol/l). The optimal 
serum concentrations of 25(OH)D begin at 75 nmol/L (30 ng/mL), and the best are between 
90-100 nmol/L (36–40 ng/mL) (7). Whether 'normal' serum levels of vitamin D are sufficient 
for immune homeostasis is not known. In 2009, a standard reference material for 25(OH)D 
became available that permits standardization of values across laboratories and may 
improve method-related variability.  
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9. Vitamin D and autoimmune diseases  
Observational studies in humans suggest an association between vitamin D deficiency and 
many rheumatological and non-rheumatological disorders, listed in Table 3.  
Rheumatological Non Rheumatologicl 
1. Rheumatoid Arthritis "RA" (3, 7, 8).  
2. Undifferentiated Connective tissue (8).  
3. SLE (8).  
4. Scleroderma (11).  
5. Ankylosing spondylitis (12).  
6. Behcet's disease (15).  
7. Psoriasis (16).  
8. Fibromylgia (17) 
1. Multiple Sclerosis "MS" (7, 8, 12, 14).  
2. Independent Diabetes Mellitus 
"IDDM" (6, 8, 12).  
3. Allergic asthma in children (9, 10).  
4. Allergic rhinitis (10).  
5. Grave's disease (13).  
SLE: Systemic lupus erythematosis, 25(OH)D: serum vitamin D level 
Table 3. Disorders that have been linked to 25(OH)D 
10. Vitamin D level and vitamin D supplementation in autoimmune diseases  
10.1 Rheumatoid Arthritis (RA) 
Rheumatoid arthritis is an immune-mediated disease, mainly driven by Th1 cells. The 
characteristic features of the disease are erosive arthritis and joint destruction, which lead to 
severe disability and increased mortality. In various animal models of RA, such as CIA in 
mice, the disease-modifying effect of VDR ligands has been widely investigated. With 1, 
25(OH)2D3 vitamin treatment in the early phase, collagen-induced arthritis was preventable 
to a certain extent and the progression of arthritis decreased (18).  
 In the last few years, the possible role of vitamin D in the pathogenesis, activity, and 
treatment of RA has been raised based on the results and observations of clinical and 
laboratorial studies(3). There have been 7case control studies evaluating vitamin D in RA 
patients. Two studies showed lower level of 25(OH)D than controls but 5 did not. In these 
studies the prevalence of low 25(OH)D was found to be between 30-63%. The rationale for 
relating vitamin D deficiency and RA is based on two facts: evidence indicate that patients with 
RA have vitamin D deficiency and the presence of 1, 25(OH) and VDR in macrophages, 
chondrocytes, and synovial cells in the joints of these patients with RA (3).  
Low sun exposure and reduced body mass index (BMI) are well established risk factors for 
vitamin D deficiency in RA patients (19). Few studies have examined dietary or nutritional 
intake prior to RA onset, and none have assessed the association of vitamin D with disease 
onset. Linda et al. found that greater intake (highest versus lowest tertile) of total daily 
vitamin D was inversely associated with risk of RA. Inverse associations were apparent for 
both dietary and supplemental vitamin D. (20). The relationship between polymorphisms of 
the VDR gene and the onset of RA activity has been demonstrated in a study in which 
patients with BB or Bb genotypes for VDR had higher indices in the health assessment 
questioner (HAQ), erythrocyte sedimentation rate (ESR), cumulative dose of corticosteroids, 
and number of disease-modifying anti-rheumatic drugs (DMARDs) when compared to 
patients with the BB genotype (3).  
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In collagen-induced arthritis models, dietarian supplementation or oral administration of 
vitamin D prevented the development or delayed the progression of arthritis(3). In an open 
labeled study with 19 patients with RA treated with traditional DMARDs, oral 
supplementation with high doses of alfacalcidol for three months reduced the severity of the 
symptoms in 89% of the patients, 45% of which achieved complete remission and 44% had 
satisfactory results. Higher incidence of side effects, such as hypercalcemia, was not 
observed (3).  
There also seem to be an inverse relationship between disease activity and the concentration 
of vitamin D metabolites in patients with inflammatory arthritis. A UK study that involved 
206 patients demonstrated that at baseline in the pre-treatment patients, there was an 
inverse association between levels of 25(OH)D and the number of painful joints, DAS28, and 
HAQ. For each increase in 10 ng/mL in vitamin D serum levels, the DAS28 reduced by 0. 3 
points and the levels of CRP by 25%. But at 1 year the only observation is the inverse 
association with HAQ score (3).  
10.2 Systemic Lupus Erythematous (SLE) 
Several studies have demonstrated a higher prevalence of vitamin D deficiency in SLE 
patients when compared to individuals with other rheumatologic diseases and healthy 
controls(3). Huisman et al. observed that 50% of SLE patients had vitamin D deficiency (cut 
off <50 nmol/L or 20 ng/mL) (21).  
Patients with systemic lupus erythematosus have multiple risk factors for 25(OH)D 
deficiency:(3) 
1. Photosensitivity: 
Is the characteristic of the disease, and the recommendation to apply sunscreen are 
responsible for lower sun exposure, decreasing the production of vitamin D in the skin.  
2. Chronic treatment with corticosteroids and hydroxichloroquine: 
These medications seem to affect vitamin D metabolism, although the evidence for this is 
not yet clear.  
3. Severe renal involvement:  
This affects the hydroxylation step of 25(OH)D.  
4. African descent: 
Severe lupus is more prevalent in people of African descent. It is believed that vitamin D 
deficiency in this group is a consequence of not only genetic factors, but it is speculated that 
lower serum concentrations of 25(OH)D, due to the lower cutaneous conversion rate 
secondary to skin color, would be another important factor.  
It has been observed that critical levels of vitamin D (<10 ng/mL) are more common in 
patients with renal involvement and photosensitive skin lesions (4).  
The association between low 25(OH)D and disease activity scores, according to the SLEDAI 
(Systemic Lupus Erythematosus Disease Activity Index) and ECLAM (European Consensus 
Lupus Activity Measurement) has been documented (3).  
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Thudi et al. demonstrated that functional assessment using combined scores (modified HAQ, 
global VAS by the patient, and fatigue scale) was worse in patients with probable or 
confirmed diagnosis of lupus and vitamin D deficiency. However, this study did not 
demonstrate an association between vitamin D deficiency and the levels of auto-antibodies, 
including anti-DNA (22).  
Carvalho et al. investigated the presence of anti-vitamin D antibodies in the serum of SLE 
patients to better explain vitamin D deficiency in autoimmune diseases. One-hundred and 
seventy-one SLE patients were investigated and 4% of them had vitamin D antibodies but 
the levels of 25(OH)D were similar in patients with or without those autoantibodies. Among 
the clinical and laboratorial associations investigated, the presence of anti-dsDNA was the 
only one that showed a strong relationship with anti-vitamin D antibodies (23).  
10.3 Ankylosing Spondylitis AS 
Osteoprosis is frequent in AS and high disease activity which assessed by Bath Ankylosing 
Spondylitis Disease Activity Index (BASDAI) is associated with an alteration in vitamin D 
metabolites and increased levels of bone resorption (11).  
The inflammatory activity in AS itself plays a major role in the pathophysiology of bone 
loss, this may be mediated in AS by substances regulating both the inflammatory process 
and bone turnover. High levels of proinflammatory cytokines such asinterleukin-1 and 
tumor necrosis factor α (TNFα) are thought to play a major role in chronic inflammation and 
act on osteroblasts and osteoclasts(12). A prospective study demonstrated a significant loss 
of bone mass in early AS with a strong association with inflammatory activity (24).  
Factors may contribute to the development of osteopenia/osteoporosis in AS: (12) 
1. Treatment of AS.  
2. Hormone disorder.  
3. Decreased mobility or physical activity.  
Patients with AS and osteoporosis had significantly higher values for ESR, CRP, and urine-
cross-links, and significantly decreased results in 1. 25 D3, 25 D3 and PTH, but no 
differences in serum calcium, serum calcium corrected for albumin, bone-AP and daily renal 
calcium excretion were observed (12).  
Clinical studies have reported the impact of vitamin D in AS as an endogenous immune 
modulator, suppressing activated T cells and cell proliferation that may accelerate the 
inflammation process (25).  
10.4 Undifferentiated Connective Tissue Disease (UCTD) 
A study by Zold et al. demonstrated the presence of a seasonal variation in the levels of 
25(OH)D in patients with UCTD and that those levels were lower in this population than in 
the control population. In this same study, 21. 7% of patients with UCTD and vitamin D 
deficiency developed established connective tissue disease (especially RA, SLE, Sjgren’s 
syndrome, and mixed connective tissue disease); their mean 25(OH)D was lower than that 
of patients who remained with undifferentiated disease, 14. 7 ± 6. 45 ng/mL vs  
33. 0 ± 13. 4 ng/mL, P =0. 0001 respectively (26). The presence of dermatological symptoms 
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(photosensitivity, erythema, and chronic discoid rash) and pleuritis was associated with low 
levels of vitamin D.  
11. The immunological basis for the vitamin D role in preventing 
autoimmunity 
Prospective studies available for the 4 major autoimmune diseases:RA, SLE, MS, and type 1 
DM, have demonstrated the beneficial effects of vitamin D supplementation in modulating 
the components of the immune system responsible for the inflammation, such as the 
expression of cytokines, growth factors, nitrous oxide, and metalloproteinase(3). A recent 
systematic review concluded that total number of studies are small, so no conclusion could 
be made with regards to the importance of 25(OH)D in preventing autoimmune disease.  
12. Summary 
The vitamin D endocrine system is recognized as an important immune modulatory factor 
involved in autoimmune diseases. VDR agonists seem primarily to inhibit DC 
differentiation, pathogenic pro-inflammatory T cells such as Th1 and Th17 cells and, under 
appropriate conditions, they seem to favour a deviation to the Th2 pathway. These 
immunomodulatory and anti-inflammatory activities might be particularly efficient in RA, 
SLE, Ankylosing spondylitis and UCTD patients and support a therapeutic role of 1, 
25(OH)2D in such a disease.  
In addition, vitamin D may play an important role in the maintenance of B-cell homeostasis, 
and the correction of vitamin D deficiency may be useful in the treatment of B cell-mediated 
autoimmune rheumatic disorders such as SLE.  
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